Whereas ketoconazole is often used to study the worst-case scenario for clinical
pharmacokinetic drug-drug interactions (DDIs) for drugs that are primarily metabolized by …

A novel in vitro model was recently developed in our laboratories for the prediction of
magnitude of clinical pharmacokinetic drug-drug interactions (DDIs), based on reversible …

Ketoconazole has generally been used as a standard inhibitor for studying clinical
pharmacokinetic drug-drug interactions (DDIs) of drugs that are primarily metabolized by …

Time-dependent inactivation (TDI) of human cytochromes P450 3A4 (CYP3A4) is a major
cause of clinical drug-drug interactions (DDIs). Human liver microsomes (HLM) are …

Cryopreserved human hepatocytes suspended in human plasma (HHSHP) represent an
integrated metabolic environment for predicting drug-drug interactions (DDIs). In this study …

Accurate prediction of drug-drug interactions (DDI) is a challenging task in drug discovery
and development. It requires determination of enzyme inhibition in vitro which is highly …

Cytochrome P450 3A (CYP3A) is a frequent target for time-dependent inhibition (TDI) that
can give rise to drug-drug interactions (DDI). Yet many drugs that exhibit in vitro TDI for …

The clinical impact of drug-drug interactions based on time-dependent inhibition of
cytochrome P450 (CYP) 3A4 has often been overpredicted, likely due to use of improper …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Numerous retrospective analyses
have shown the utility of in vitro systems for predicting potential drug–drug interactions …

Abstract Background and Objectives: An approach was recently proposed for quantitative
predictions of cytochrome P450 (CYP) 3A4-mediated drug-drug interactions. This approach …